Fact CheckerSign in

NCT06806189Not yet recruitingEarly phase 1

Lipiodal Injection Technique for Free Flap Sparing Adjuvant RT Planning in HNC

Lipiodal Injection Technique for Free Flap Sparing Adjuvant Radiation Planning in Head and Neck Cancer

Source: ClinicalTrials.gov · Last updated 3 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open

Brief summary (registry, in English)

Patients with advanced mouth/throat cancers require surgery to remove the cancer followed by reconstruction with transplanted skin/muscle/bone from another location in their body to restore function. This is called a free-flap (skin/muscle/bone used from another part of the body to reconstruct the cancer site). Post-operative radiation therapy is often recommended to reduce the risk of cancer coming back. Unfortunately, radiation can exacerbate issues with swallowing and speech and lead to other complications. To date, there has been no mechanism to allow sparing of the healthy tissue from radiation while ensuring delivery to all at-risk areas. This is a proof-of-principle study that injects a safe contrast agent (material injected to enhance x-ray and ct images) at the time of surgery to improve delineation of the interface between the removed mouth/throat cancer and the healthy tissue reconstructing the defect. In doing so, the investigators hope to demonstrate the potential to spare post-operative radiation to the healthy reconstructive tissue and improve patient function. The investigators propose using Lipiodal, a poppyseed oil-extract that has been in safe clinical use for \> 100-years, in 10 patients. There will be no change to the way in which patients are treated for their mouth/throat cancer or in the way radiation is delivered. The investigators will assess the feasibility and safety of injecting Lipiodal at the time of surgery and visualization on post-operative CT scans. This has been shown to be both safe and feasible in patients with other cancers, such as bladder cancer, however patients will be closely monitored for any side effects. Patients will provide informed consents and be able to withdraw at any time.

Status (registry)
Not yet recruiting
Phase (registry)
Early phase 1
Study type
Interventional
Enrollment
10 (estimated)
First submitted
20 Jan 2025
Start date
1 Apr 2025
Primary completion date
30 Mar 2026
Lead sponsor
Western University, Canada
NCT number
NCT06806189

What you commit to

  • Study type: Interventional · Early phase 1
  • Planned participants: 10
  • From 1 Apr 2025 to the primary completion date, 30 Mar 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Previous treated locally advanced head and neck cancer with surgery and/or radiation

Other illness

  • History of hypersensitivity or adverse reaction to Lipiodal or any iodinated radiocontrast
  • Clinically apparent cognitive impairment

Other

  • Severe bronchial asthma
  • Severe renal dysfunction
  • Hyperthyroidism
  • Pregnant
  • Breastfeeding

Who the study is looking for

  • Adult patients (18 years and older) seen at the head and neck clinic at London Health Sciences Centre (LHSC)
  • Locally advanced T2-4N0-3M0 mucosal or cutaneous squamous cell carcinoma involving the oral cavity requiring composite resection and free flap reconstruction

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Western University
Coordinator of this site? Confirm its status
LondonCanadaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.